DETERMINATION OF WHOLE-BLOOD EVEROLIMUS CONCENTRATIONS IN KIDNEY TRANSPLANT RECIPIENTS USING THE INNOFLUOR FPIA

2010 ◽  
Vol 90 ◽  
pp. 950
Author(s):  
H. S. CIFTCI ◽  
T. K. AYNA ◽  
Y. Caliskan ◽  
H. TOZKIR ◽  
G. ISITMANGIL ◽  
...  
2018 ◽  
Vol 20 (5) ◽  
pp. e12969 ◽  
Author(s):  
Camila Silva Bicalho ◽  
Renato dos Reis Oliveira ◽  
Daísa Ribeiro David ◽  
Maria Cristina Domingues Silva Fink ◽  
Fabiana Agena ◽  
...  

2013 ◽  
Vol 04 (10) ◽  
pp. 27-35 ◽  
Author(s):  
Lars Wilhelm ◽  
Martin Nitschke ◽  
Markus Meier ◽  
Reinhard Vonthein ◽  
Jan Kramer

PLoS ONE ◽  
2016 ◽  
Vol 11 (12) ◽  
pp. e0166547 ◽  
Author(s):  
Michael Ke Wang ◽  
Christine White ◽  
Ayub Akbari ◽  
Pierre Brown ◽  
Naser Hussain ◽  
...  

F1000Research ◽  
2015 ◽  
Vol 4 ◽  
pp. 913
Author(s):  
Gareth Betts ◽  
Jeroen Van Der Net ◽  
Sushma Shankar ◽  
Peter Friend ◽  
Paul Harden ◽  
...  

New biomarkers are required to detect acute rejection (AR) in kidney transplant recipients (KTRs) to avoid invasive kidney biopsies. We assess whether a 5-gene panel (DUSP1; NKTR; PBEF1; MAPK9; and PSEN1) in whole blood samples that has previously been shown to identify AR in a paedriatric KTR population is able to distinguish AR in a UK population of adult Caucasian KTR patients.


F1000Research ◽  
2016 ◽  
Vol 4 ◽  
pp. 913
Author(s):  
Gareth Betts ◽  
Jeroen Van Der Net ◽  
Sushma Shankar ◽  
Peter Friend ◽  
Paul Harden ◽  
...  

New biomarkers are required to detect acute rejection (AR) in kidney transplant recipients (KTRs) to avoid invasive kidney biopsies. We assess whether a 5-gene panel (DUSP1; NKTR; PBEF1; MAPK9; and PSEN1) in whole blood samples that has previously been shown to identify AR in a paedriatric KTR population is able to distinguish AR in a UK population of adult Caucasian KTR patients.


PLoS ONE ◽  
2020 ◽  
Vol 15 (8) ◽  
pp. e0238062
Author(s):  
Tiziana Lazzarotto ◽  
Angela Chiereghin ◽  
Antonio Piralla ◽  
Dino Gibertoni ◽  
Giulia Piccirilli ◽  
...  

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Volkan Polatkan ◽  
Ebru Ozdemir ◽  
Turker Erturk ◽  
Emel Tatli ◽  
Ibrahim Berber ◽  
...  

Abstract Background and Aims Both under and over-dosing of tacrolimus may compromise clinical outcomes by exposing patients to either the risks of graft rejection or adverse events (AEs) associated with immunosuppressive therapy. This study is designed to compare the clinical follow-up of our kidney transplant recipients receiving once-daily, prolonged-release (PR-T; Advagraf) and twice-daily, immediate-release (IR-T; Prograf) tacrolimus in the early posttransplant period. Method This randomized study included 78 de novo, adult kidney transplant recipients to PR-T 0.15 mg/kg/day (Group I=39) and IR-T 0.15 mg/kg/day (Group II=39) for seven days in the posttransplant period. Demographic features and clinical parameters regarding levels of whole blood tacrolimus and serum creatinine were compared between the two groups. Presence of acute rejection and AEs were investigated. Dose adjustments were permitted to target a pre-defined therapeutic range based on measured trough blood concentrations in all patients. SPSS 15 for Windows was used for statistical analysis. Results None of the patients suffered from acute rejection and there were no AEs in the early posttransplant period. However, Group II patients were found to have higher whole blood tacrolimus levels on the posttransplant 1st, 4th and 7th days (p=0.02, p=0.009 and p=0.013 respectively). Also serum creatinine levels were significantly increased in Group II patients on the posttransplant 7th day (p=0.02). Conclusion Prolonged release tacrolimus seems promising in preventing acute transplant rejection with adequate blood levels, as well as making it possible to avoid the interindividual variation in absorption and early calcineurin inhibitor toxicity.


2013 ◽  
Vol 82 (2) ◽  
pp. 83-92 ◽  
Author(s):  
C. Süsal ◽  
D. L. Roelen ◽  
G. Fischer ◽  
E. F. Campos ◽  
M. Gerbase-DeLima ◽  
...  

2001 ◽  
Vol 47 (9) ◽  
pp. 1679-1687 ◽  
Author(s):  
Raffaele Caruso ◽  
Norberto Perico ◽  
Dario Cattaneo ◽  
Giampiero Piccinini ◽  
Samantha Bonazzola ◽  
...  

Abstract Background: In transplant patients, current cyclosporine (CsA) dose monitoring with classic pharmacokinetics has demonstrated limitations. Evaluation of the activity of calcineurin (CN), the serine-threonine phosphatase enzyme target of CsA, has been proposed as a reliable way to optimize CsA dosing. Methods: CN activity was measured in whole blood in an attempt to overcome the high variability of results obtained previously with peripheral blood mononuclear cells (PBMCs). We also explored, in vitro, a possible relationship between the CsA concentration and CN inhibition in whole blood. Finally, we assessed whether the CsA blood trough concentration correlates with whole-blood CN activity in kidney transplant recipients (n = 15) on maintenance immunosuppression with CsA. Results: In 14 healthy individuals, less scattered CN activity values were documented in whole blood than in the PBMC fraction. Whole-blood CN activity was higher than the sum of the enzyme activity in each cell blood fraction. After ex vivo incubation of whole blood from healthy subjects (n = 5) with increasing concentrations of CsA (50–1000 μg/L for 1 h), a concentration-dependent inhibition of CN activity was found comparable to that in the PBMC fraction. Moreover, in 15 kidney transplant recipients, no relationship was found between CsA pharmacokinetic parameters and CN activity at time 0. However, a highly significant correlation was found between CN area under the CN activity-time curve, which represents the extent of the CN daily inhibition, and CN activity at time 0 (r = 0.79; P <0.01) and at 12 h postdosing (r = 0.96; P <0.01). Conclusions: Measuring CN activity in whole-blood samples is a reproducible method. In kidney transplant recipients, CsA trough concentrations do not predict baseline CN activity. Moreover, a single CN activity monitoring at baseline or at time 12 h post-CsA dosing may be a useful surrogate for the inhibition of this enzyme by CsA during 12 h.


Sign in / Sign up

Export Citation Format

Share Document